Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure

Journal of Molecular and Cellular Cardiology

Volumn 36, Issue 5, 2004, Pages 683-690

  Lou, H ^a   Danelisen, I ^a   Singal, P K ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cytokines; Dilated cardiomyopathy; Doxorubicin

Indexed keywords

CYTOKINE; DOXORUBICIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CARDIOMYOPATHY; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; HEART FAILURE; HEART MUSCLE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; BODY WEIGHT; CARDIOMYOPATHIES; CYTOKINES; DOXORUBICIN; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; MALE; MYOCARDIUM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; UP-REGULATION;

EID: 2342478428     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2004.03.004     Document Type: Article

References (54)

1. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 32:(2):1973;302-314
2. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl J Med. 339:(13):1998;900-905
3. Shan K., Lincoff A.M., Young J.B. Anthracycline-induced cardiotoxicity. Ann Intern Med. 125:(1):1996;47-58
4. Singal P.K., Iliskovic N., Li T., Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 11:(12):1997;931-936
5. Kumar D., Kirshenbaum L., Li T., Danelisen I., Singal P. Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Ann NY Acad Sci. 874:1999;156-168
6. Kumar D., Kirshenbaum L.A., Li T., Danelisen I., Singal P.K. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal. 3:(1):2001;135-145
7. Arola O.J., Saraste A., Pulkki K., Kallajoki M., Parvinen M., Voipio-Pulkki L.M. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 60:(7):2000;1789-1792
8. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. New Engl J Med. 323:(4):1990;236-241
9. Long C.S. The role of interleukin-1 in the failing heart. Heart Fail Rev. 6:(2):2001;81-94
10. Torre-Amione G., Kapadia S., Lee J., Bies R.D., Lebovitz R., Mann D.L. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 92:(6):1995;1487-1493
11. Wollert K.C., Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 6:(2):2001;95-103
12. Gerling I.C., Sun Y., Ahokas R.A., Wodi L.A., Bhattacharya S.K., Warrington K.J., et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol. 285:(2):2003
13. Pagani F.D., Baker L.S., Hsi C., Knox M., Fink M.P., Visner M.S. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. J Clin Invest. 90:(2):1992;389-398
14. Bozkurt B., Kribbs S.B., Clubb F.J. Jr, Michael L.H., Didenko V.V., Hornsby P.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 97:(14):1998;1382-1391
15. Kubota T., McTiernan C.F., Frye C.S., Slawson S.E., Lemster B.H., Koretsky A.P., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 81:(4):1997;627-635
16. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:(5068):1992;387-389
17. Ungureanu-Longrois D., Balligand J.L., Kelly R.A., Smith T.W. Myocardial contractile dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J Mol Cell Cardiol. 27:(1):1995;155-167
18. Yokoyama T., Vaca L., Rossen R.D., Durante W., Hazarika P., Mann D.L. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 92:(5):1993;2303-2312
19. Krown K.A., Page M.T., Nguyen C., Zechner D., Gutierrez V., Comstock K.L., et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 98:(12):1996;2854-2865
20. Sugamori T., Ishibashi Y., Shimada T., Takahashi N., Sakane T., Ohata S., et al. Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cardiomyopathy: close correlation of tumor necrosis factor-alpha with systemic and local production of nitric oxide. Circ J. 66:(7):2002;627-632
21. Sharma R., Anker S.D. Immune and neurohormonal pathways in chronic heart failure. Congest Heart Fail. 8:(1):2002;23-28. 48
22. Tabet J.Y., Lopes M.E., Champagne S., Su J.B., Merlet P., Hittinger L. Inflammation, cytokines and anti-inflammatory therapies in heart failure. Arch Mal Coeur Vaiss. 95:(3):2002;204-212
23. Siveski-Iliskovic N., Hill M., Chow D.A., Singal P.K. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation. 91:(1):1995;10-15
24. Siveski-Iliskovic N., Kaul N., Singal P.K. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation. 89:(6):1994;2829-2835
25. Li T., Danelisen I., Bello-Klein A., Singal P.K. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res. 46:(3):2000;523-530
26. Abe K., Tokumura M., Ito T., Murai T., Takashima A., Ibii N. Involvement of iNOS in postischemic heart dysfunction of stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 280:(2):2001;H668-H673
27. Kotani N., Takahashi S., Sessler D.I., Hashiba E., Kubota T., Hashimoto H., et al. Volatile anesthetics augment expression of proinflammatory cytokines in rat alveolar macrophages during mechanical ventilation. Anesthesiology. 91:(1):1999;187-197
28. Von Hoff D.D., Layard M.W., Basa P., Davis H.L. Jr, Von Hoff A.L., Rozencweig M., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 91:(5):1979;710-717
29. Jones S.M., Kirby M.S., Harding S.E., Vescova G., Wanless R.B., Dalla Libera L.D., et al. Adriamycin cardiomyopathy in the rabbit: alterations in contractile proteins and myocyte function. Cardiovasc Res. 24:(10):1990;834-842
30. Singal P.K., Siveski-Iliskovic N., Hill M., Thomas T.P., Li T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol. 27:(4):1995;1055-1063
31. Safrit J.T., Bonavida B. Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. Cancer Res. 52:(23):1992;6630-6637
32. Watanabe N., Okamoto T., Tsuji N., Sasaki H., Akiyama S., Kobayashi D., et al. Reversal of tumor necrosis factor resistance in tumor cells by adriamycin via suppression of intracellular resistance factors. Jpn J Cancer Res. 86:(4):1995;395-399
33. Wada H., Saito K., Kanda T., Kobayashi I., Fujii H., Fujigaki S., et al. Tumor necrosis factor-alpha (TNF-alpha) plays a protective role in acute viralmyocarditis in mice: a study using mice lacking TNF-alpha. Circulation. 103:(5):2001;743-749
34. Arinaga S., Akiyoshi T., Tsuji H. Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res. 46:(8):1986;4213-4216
35. Salazar D., Cohen S.A. Multiple tumoricidal effector mechanisms induced by adriamycin. Cancer Res. 44:(6):1984;2561-2566
36. Mustapha S., Kirshner A., De Moissac D., Kirshenbaum L.A. A direct requirement of nuclear factor-kappa B for suppression of apoptosis in ventricular myocytes. Am J Physiol Heart Circ Physiol. 279:(3):2000;H939-H945
37. Murray D.R., Freeman G.L. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res. 78:(1):1996;154-160
38. Dibbs Z.I., Diwan A., Nemoto S., DeFreitas G., Abdellatif M., Carabello B.A., et al. Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation. 108:(8):2003;1002-1008
39. Yokoyama T., Nakano M., Bednarczyk J.L., McIntyre B.W., Entman M., Mann D.L. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 95:(5):1997;1247-1252
40. Haudek S.B., Bryant D.D., Giroir B.P. Differential regulation of myocardial NF kappa B following acute or chronic TNF-alpha exposure. J Mol Cell Cardiol. 33:(6):2001;1263-1271
41. Heba G., Krzeminski T., Porc M., Grzyb J., Ratajska A., Dembinska-Kiec A. The time course of tumor necrosis factor-alpha, inducible nitric oxide synthase and vascular endothelial growth factor expression in an experimental model of chronic myocardial infarction in rats. J Vasc Res. 38:(3):2001;288-300
42. Diwan A., Dibbs Z., Nemoto S., DeFreitas G., Carabello B.A., Sivasubramanian N., et al. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 109:(2):2004;262-268
43. Watanabe N., Tsuji N., Tsuji Y., Sasaki H., Okamoto T., Akiyama S., et al. Endogenous tumor necrosis factor inhibits the cytotoxicity of exogenous tumor necrosis factor and adriamycin in pancreatic carcinoma cells. Pancreas. 13:(4):1996;395-400
44. Li T., Singal P.K. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation. 102:(17):2000;2105-2110
45. Li T., Danelisen I., Singal P.K. Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. Mol Cell Biochem. 232:(1-2):2002;19-26
46. Wong G.H., Goeddel D.V. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science. 242:(4880):1988;941-944
47. Kiningham K.K., Xu Y., Daosukho C., Popova B., St Clair D.K. Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2. Biochem J. 353:(Pt 1):2001;147-156
48. Yen H.C., Oberley T.D., Vichitbandha S., Ho Y.S., St Clair D.K. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest. 98:(5):1996;1253-1260
49. McGowan B.S., Ciccimaro E.F., Chan T.O., Feldman A.M. The balance between pro-apoptotic and anti-apoptotic pathways in the failing myocardium. Cardiovasc Toxicol. 3:(3):2003;191-206
50. Kallen K.J. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta. 1592:(3):2002;323-343
51. Negoro S., Oh H., Tone E., Kunisada K., Fujio Y., Walsh K., et al. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation. 103:(4):2001;555-561
52. Loppnow H., Westphal E., Buchhorn R., Wessel A., Werdan K. Interleukin-1 and related proteins in cardiovascular disease in adults and children. Shock. 16:(Suppl 1):2001;3-9
53. Tian B., Liu J., Bitterman P.B., Bache R.J. Mechanisms of cytokine induced NO-mediated cardiac fibroblast apoptosis. Am J Physiol Heart Circ Physiol. 283:(5):2002;H1958-H1967
54. Fortunato S.J., Menon R. IL-1beta is a better inducer of apoptosis in human fetal membranes than IL-6. Placenta. 24:(10):2003;922-928